Literature DB >> 8709195

The zinc finger of nucleocapsid protein of Friend murine leukemia virus is critical for proviral DNA synthesis in vivo.

Q Yu1, J L Darlix.   

Abstract

Nucleocapsid protein NCp10 of murine leukemia virus (MuLV) is encoded by the 3' domain of gag and contains a zinc finger of the form Cys-X2-Cys-X4-His-X4-Cys flanked by basic amino acids. In the course of virus assembly, NCp10 is necessary for core formation, and the zinc finger flanked by the basic residues is required for the packaging of the genomic RNA dimer. In vitro, NCp10 exhibits strong nucleic acid binding and annealing activities that appear to be critical for virus infectivity since NCp10 promotes dimerization of the viral RNA containing the E/DLS packaging-dimerization signal and annealing of replication primer tRNA(Pro) to the initiation site of reverse transcription (PBS). Recent in vitro studies have suggested that NCp10 may also play a role in proviral DNA synthesis. To investigate the function of NCp10 in proviral DNA synthesis in vivo, we developed a simple and convenient genetic packaging system consisting of two DNA constructs expressing the packaging components gag-pol and env of Friend MuLV and a Moloney MuLV-based lacZ vector with either the MuLV E+ or a rat VL30 E packaging signal. This system allowed us to examine the consequences of a set of mutations in NCp10 on a single round of recombinant virus replication. Most mutations in the N- or C-terminal domain of NCp10 do not significantly alter infectivity, while those in the zinc finger drastically impair infectivity. Analysis of the viral RNA content in virions showed that all mutations in the zinc finger decrease but do not abolish packaging of the recombinant genome. Interestingly enough, mutation of Y-28 to S (mutation Y28S) in the zinc finger results in RNA packaging at a level similar to that observed upon deletion of three prolines and three arginines in the C-terminal domain of NCp10 (mutant delta PR3). However, mutant Y28S is noninfectious while mutant delta PR3 is only threefold less infectious than the wild-type virus, which prompted us to examine the role of NCp10 protein in proviral DNA synthesis in vivo using these nucleocapsid mutants. PCR amplification was used to analyze viral DNA synthesized in newly infected cells, and results indicate that the Y28S zinc finger mutation impairs reverse transcription, thus suggesting that the nucleocapsid protein zinc finger plays a key role in proviral DNA synthesis in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8709195      PMCID: PMC190593          DOI: 10.1128/JVI.70.9.5791-5798.1996

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Production of high-titer helper-free retroviruses by transient transfection.

Authors:  W S Pear; G P Nolan; M L Scott; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

2.  Interactions between HIV-1 nucleocapsid protein and viral DNA may have important functions in the viral life cycle.

Authors:  M Lapadat-Tapolsky; H De Rocquigny; D Van Gent; B Roques; R Plasterk; J L Darlix
Journal:  Nucleic Acids Res       Date:  1993-02-25       Impact factor: 16.971

3.  Specific binding of human immunodeficiency virus type 1 gag polyprotein and nucleocapsid protein to viral RNAs detected by RNA mobility shift assays.

Authors:  R D Berkowitz; J Luban; S P Goff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

4.  Two short basic sequences surrounding the zinc finger of nucleocapsid protein NCp10 of Moloney murine leukemia virus are critical for RNA annealing activity.

Authors:  H De Rocquigny; D Ficheux; C Gabus; B Allain; M C Fournie-Zaluski; J L Darlix; B P Roques
Journal:  Nucleic Acids Res       Date:  1993-02-25       Impact factor: 16.971

5.  Nucleocapsid zinc fingers detected in retroviruses: EXAFS studies of intact viruses and the solution-state structure of the nucleocapsid protein from HIV-1.

Authors:  M F Summers; L E Henderson; M R Chance; J W Bess; T L South; P R Blake; I Sagi; G Perez-Alvarado; R C Sowder; D R Hare
Journal:  Protein Sci       Date:  1992-05       Impact factor: 6.725

6.  A small and efficient dimerization/packaging signal of rat VL30 RNA and its use in murine leukemia virus-VL30-derived vectors for gene transfer.

Authors:  C Torrent; C Gabus; J L Darlix
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

7.  Three-dimensional 1H NMR structure of the nucleocapsid protein NCp10 of Moloney murine leukemia virus.

Authors:  H Déméné; N Jullian; N Morellet; H de Rocquigny; F Cornille; B Maigret; B P Roques
Journal:  J Biomol NMR       Date:  1994-03       Impact factor: 2.835

8.  Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein.

Authors:  T Dorfman; J Luban; S P Goff; W A Haseltine; H G Göttlinger
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

9.  The two zinc fingers in the human immunodeficiency virus type 1 nucleocapsid protein are not functionally equivalent.

Authors:  R J Gorelick; D J Chabot; A Rein; L E Henderson; L O Arthur
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

10.  Transactivation of the minus-strand DNA transfer by nucleocapsid protein during reverse transcription of the retroviral genome.

Authors:  B Allain; M Lapadat-Tapolsky; C Berlioz; J L Darlix
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

View more
  14 in total

1.  Identification of residues of the Moloney murine leukemia virus nucleocapsid critical for viral DNA synthesis in vivo.

Authors:  J Gonsky; E Bacharach; S P Goff
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity.

Authors:  S Druillennec; C Z Dong; S Escaich; N Gresh; A Bousseau; B P Roques; M C Fournié-Zaluski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

3.  Subtle alterations of the native zinc finger structures have dramatic effects on the nucleic acid chaperone activity of human immunodeficiency virus type 1 nucleocapsid protein.

Authors:  Jianhui Guo; Tiyun Wu; Bradley F Kane; Donald G Johnson; Louis E Henderson; Robert J Gorelick; Judith G Levin
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  A small region of the ecotropic murine leukemia virus (MuLV) gag gene profoundly influences the types of polytropic MuLVs generated in mice.

Authors:  M Lavignon; J Richardson; L H Evans
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 5.  Nucleocapsid protein function in early infection processes.

Authors:  James A Thomas; Robert J Gorelick
Journal:  Virus Res       Date:  2008-02-14       Impact factor: 3.303

6.  Transduction of nondividing human macrophages with gammaretrovirus-derived vectors.

Authors:  Loraine Jarrosson-Wuilleme; Caroline Goujon; Jeanine Bernaud; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 nucleocapsid protein promotes efficient strand transfer and specific viral DNA synthesis by inhibiting TAR-dependent self-priming from minus-strand strong-stop DNA.

Authors:  J Guo; L E Henderson; J Bess; B Kane; J G Levin
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

8.  Zinc finger structures in the human immunodeficiency virus type 1 nucleocapsid protein facilitate efficient minus- and plus-strand transfer.

Authors:  J Guo; T Wu; J Anderson; B F Kane; D G Johnson; R J Gorelick; L E Henderson; J G Levin
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Targeting of murine leukemia virus gag to the plasma membrane is mediated by PI(4,5)P2/PS and a polybasic region in the matrix.

Authors:  E Hamard-Peron; F Juillard; J S Saad; C Roy; P Roingeard; M F Summers; J-L Darlix; C Picart; D Muriaux
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

Review 10.  When is it time for reverse transcription to start and go?

Authors:  Marylène Mougel; Laurent Houzet; Jean-Luc Darlix
Journal:  Retrovirology       Date:  2009-03-04       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.